Reference : Familial aggregation and antimicrobial response dose-dependently affect the risk for ...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/38482
Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease.
English
Joossens, Marie [> > > >]
Van Steen, Kristel mailto [Université de Liège - ULg > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique >]
Branche, Julien [> > > >]
Sendid, Boualem [> > > >]
Rutgeerts, Paul [> > > >]
Vasseur, Francis [> > > >]
Poulain, Daniel [> > > >]
Broly, Franck [> > > >]
Colombel, Jean*-Frederic [> > > >]
Vermeire, Severine [> > > >]
Chamaillard, Mathias [> > > >]
2010
Inflammatory Bowel Diseases
Lippincott Williams & Wilkins
16
1
58-67
Yes (verified by ORBi)
International
1078-0998
1536-4844
Hagerstown
MD
[en] antimicrobial antibodies ; disease prediction ; familial aggregation ; ibd incidence ; nod2 ; inflammatory-bowel-disease ; antineutrophil cytoplasmic antibodies ; clinical characteristics ; age ; anticipation ; concordance ; prevalence ; diagnosis ; belgium ; couples
[en] BACKGROUND:: An increased risk of Crohn's disease (CD) has been reported consistently in first-degree relatives of patients. Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk. METHODS:: We investigated 86 families from Belgium and northern France, 45 with at least 3 first-degree relatives with CD, 24 with a single case, and 17 control families without inflammatory bowel disease (IBD). The cohort consisted of 186 CD patients, 290 healthy relatives, and 142 controls (total 618). Genetic (NOD2, NOD1, TLR4, CARD8) and serologic markers (ASCA, ACMA, ALCA, ACCA, ASigmaMA, OmpC, CBir1, I2) were determined in all subjects. All Belgian families were prospectively followed up for 54 months. RESULTS:: In multiple-affected families, an increment of affected first-degree relatives and of positive antibodies were additive risks factors for CD (P < 0.0001), independent of NOD2 mutations. When comparing subjects from multiple-affected families, having 3 additional first-degree relatives with CD and 1 additional positive antibody increased the odds for CD to 9.19 (95% confidence interval [CI]: 4.07-20.80). After a follow-up of 54 months among all Belgian families, a total of 4 new diagnoses of IBD were confirmed in the multiple-affected families only, resulting in a 57-fold increase in incidence within multiple-affected families compared to the known incidence of IBD in our region. CONCLUSIONS:: We found an additive risk increment for CD in subjects from multicase families per additional affected relative and per additional positive antibody, independent of NOD2. Furthermore, a very high disease incidence was observed in these multiple-affected families. Inflamm Bowel Dis 2010.
http://hdl.handle.net/2268/38482
also: http://hdl.handle.net/2268/144364
10.1002/ibd.20985

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Joossens2010.pdfPublisher postprint260.43 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.